Pinato, D., Stavraka, C., Flynn, M., Forster, M., O’Cathail, S., Seckl, M., Kristeleit, R., Olmos, D., Turnbull, S. and Blagden, S. (2014) An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials. PLoS ONE, 9, Article ID: e83279. http://dx.doi.org/10.1371/journal.pone.0083279

has been cited by the following article:

• TITLE: Prognostic Value of Neutrophil Lymphocyte Ratio in Second Line Advanced Malignant Pleural Mesothelioma

  AUTHORS: Ahmed El Bastawisy, Maha Yahia, Abdel Rahman M. Abdel Rahman, Rabab Gaafar

  KEYWORDS: Neutrophil Lymphocyte Ratio, Mesothelioma

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.7, June 23, 2014

  ABSTRACT: Background: Malignant pleural mesothelioma is a lethal disease and hence the strong need for identifying new prognostic factors. Methods: This is a retrospective study including all eligible patients with advanced malignant pleural mesothelioma (MPM) presenting to National Cancer Institute, Cairo University. Neutrophil lymphocyte (N/L) ratio was assessed before second line chemotherapy. 2.5 was used as the cutoff point. Endpoints were the assessment of correlation between N/L ratio and clinical response (CR), progression free survival (PFS) and overall survival (OS). Results: 52 patients (19 stage III and 33 stage IV) MPM were included and followed up during the period from July 2009 till November 2012 with a median follow-up period of 2.6 months. 87.5% of patients with N/L ratio > 2.5 showed progressive disease versus 91.7% in patients with N/L ratio 2.5 versus 14% for patients with N/L ratio 2.5 versus 66% for patients with N/L ratio